Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hebei University Company In-licenses Cancer Molecule from Sareum of Britain

publication date: Dec 3, 2013
Hebei Medical University Biomedical Engineering Center (HMUBEC) in-licensed China rights to a pre-clinical cancer treatment from Sareum Holdings plc of Britain. HMUBEC is part of Hebei Medical University Science & Technology General Company (HMUSTGC), which has labs, manufacturing facilities and sales/distribution channels. Since its founding in 1992, HMUSTGC has developed more than 85 therapeutic products and medical devices for the Chinese market. More details....

Stock Symbol: (AIM: SAR)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital